| Revision as of 00:33, 11 February 2013 editStar767 (talk | contribs)3,516 edits →Sample publications: add one← Previous edit | Revision as of 00:39, 11 February 2013 edit undoStar767 (talk | contribs)3,516 edits →Career: add referenceNext edit → | ||
| Line 13: | Line 13: | ||
| With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation. These include adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit. | With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation. These include adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit. | ||
| He has been elected to the ] board of directors.<ref name=reuters>{{cite news|last=Press release|title=Celgene Corporation Elects Dr. Richard W. Barker to Its Board of Directors|url=http://www.reuters.com/article/2012/01/23/idUS79165+23-Jan-2012+BW20120123|accessdate=11 February 2013|newspaper=Reuters|date=23 January 2012}}</ref> | |||
| He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the ], and to facilitate innovations emerging from academic and industrial research into NHS application. | He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the ], and to facilitate innovations emerging from academic and industrial research into NHS application. | ||
Revision as of 00:39, 11 February 2013
 | This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Richard Barker" businessman – news · newspapers · books · scholar · JSTOR (February 2013) (Learn how and when to remove this message) |
Richard Barker is currently Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI). He has devoted much of his career to improving the process of bringing medical innovations to patients, both in the course of a long business career and as a contributor to academic research and public policy.
Education
He was educated at Alleyn's School, London and Exeter College Oxford, where he received a BA in Chemistry. He went on to focus his research on biological applications of magnetic resonance techniques, in an Oxford DPhil and in post-doctoral periods in Munich and Leeds.
Career
His business career has included both Europe and the US. After a period with McKinsey, in which he headed the European Healthcare practice and also advised UK, Swiss and US pharmaceutical companies, he held a succession of senior appointments in the US. As General Manager of IBM's healthcare business, he launched Healthvillage, one of the earliest Internet healthcare applications. At Chiron, he headed the diagnostics business, which brought the latest immunodiagnostics to market. He subsequently served as chairman and chief executive of Molecular Staging, whose genome amplification technology enables gene sequencing on rare DNA samples.
On returning to the UK, he headed the Association of the British Pharmaceutical Industry (ABPI) and initiated policy programmes in areas such as stratified medicine, and launched frameworks for translational partnerships between academia and industry. He formed and chairs Stem Cells of Safer Medicines, a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.
With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation. These include adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.
He has been elected to the Celgene Corporation board of directors.
He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the NHS, and to facilitate innovations emerging from academic and industrial research into NHS application.
Sample publications
- 2030 - the Future of Medicine
- "Adaptive drug development and licensing", Richard Barker & Sarah Garner, in Regulatory Rapporteur, Vol 9, No 10, October 2012.
- "A flexible blueprint for the future of drug development", Richard Barker, Lancet. January 2010
- Economic opportunities and threats facing personalised medicine by Dr Richard Barker, The Oxford Centre for Accelerating Medical Innovations
Personal Life
Richard lives in London, is married to Michaela Barker and has three children and a number of grandchildren. He enjoys mountain walking and music.
References
- "Dr Richard Barker OBE". CASMI. Retrieved 11 February 2013.
- "Dr Richard W. Barker". innovativiondebate.com. Retrieved 10 February 2013.
- "Richard W. Barker D.Phil., B.A., M.A." Bloomberg Business Week. Retrieved 11 February 2013.
- Press release (23 January 2012). "Celgene Corporation Elects Dr. Richard W. Barker to Its Board of Directors". Reuters. Retrieved 11 February 2013.
- http://2030healthfutures.com/
- http://www.aptivsolutions.com/wp-content/uploads/2012/09/Regulatory-Rapporteur-October-2012.pdf, Regulatory Rapporteur, coauthored with Sarah Garner
- Richard Barker a. "A flexible blueprint for the future of drug development". The Lancet. Retrieved 2013-01-28.